medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 5

<< Back Next >>

Rev Méd Electrón 2019; 41 (5)

Immunotherapy, a therapeutic option in elder people with non small cells lung cancer

Herrera SA, Carreño RIE, Camacho SK, Santiesteban ÁE, Morales FMA

Language: Portugués
References: 10
Page: 1279-1287
PDF size: 134.48 Kb.


ABSTRACT

Cancer is a priority public health problem in the world. In Cuba, it is the second cause of death in most age groups and mainly in the population aged over 60 years.
To evaluate the impact of immunotherapy as a therapeutic alternative that improves survival functions in elder patients with non-small cell lung cancer.
An experimental analytical study was carried out; the universe was composed by 123 elder people diagnosed with lung cancer who were treated with immunotherapy in Matanzas. Control variables were used to which the corresponding summary measures were applied using chi-square hypothesis tests and likelihood ratios for their analysis and statistics; survival functions were evaluated using Kaplan Meier curves.
The efficacy and safety of immunotherapy in the treatment of the studied patients was demonstrated. Therefore, the authors believe that the sequential impact of the combination of surgery, chemotherapy, radiotherapy and biological therapies tends to extend the survival of patients suffering from non-small cell lung cancer with an ethically acceptable life quality. The new immunological therapy, consisting in returning to the patients´ immunologic system the capacity of recognizing a tumor as foreign, and therefore, fighting against it, have yielded very important answers and benefits.


REFERENCES

  1. Cuba. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Cáncer de pulmón. Epidemiología y tratamiento farmacológico. Bibliomed [Internet]. 2018 [citado11/03/2019];25(8) Disponible en: http://files.sld.cu/bmn/files/2018/08/bibliomed-agosto-2018.pdf

  2. Pérez Escobar MM. Cáncer de Pulmón de Células no Pequeñas: presentación de un caso. Rev Arch Med Camagüey [Internet]. 2017[citado11/03/2019];21(2). Disponible en: http://revistaamc.sld.cu/index.php/amc/article/view/4798/2715

  3. McIntyre A, Ganti AK. Lung cancer— A global perspective. J Surg Oncol. 2017;115(5):550–554. Citado en PubMed:PMID:28418583.

  4. Valero Alvarado OM. Inmunoterapia en pacientes con Cáncer de Pulmón de Células no Pequeñas versus terapia convencional. Revisión sistemática. Argentina: Universidad del Rosario-Universidad CES;2014.

  5. Mostafa A, Morris D. Immunotherapy for lung cancer: has it finally arrived? Front Oncol. 2014;22(4):1-7. Citado en PubMed:PMID:25374843.

  6. Dolan DE, Gupta S. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control. 2014 Jul;21(3):231. Citado en PubMed: PMID:24955707.

  7. Rafiemanesh H, Mehtarpour M, Khani F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis 2016;8(6):1094-1102. Citado en PubMed:PMID:27293825

  8. Gridelli C. Management of unfit older patients with advanced NSCLC. Cancer Treat Rev.2009;35(6):517–21. Citado en PubMed:PMID:19457617.

  9. Lage A. La inmunoterapia y la complejidad: vencer las barreras para controlar el cáncer avanzado. MEDICC Rev [Internet]. 2014 [citado11/03/2019];16(3–4). Disponible en: http://mediccreview.org/wp-content/uploads/2018/04/mr_483_es.pdf

  10. Cobo M. Cáncer de Pulmón [Internet]. España: Sociedad Española de Oncología Médica [citado11/03/2019];2017. Disponible en: https://seom.org/info-sobre-elcancer/ cancer-de-pulmon?showall=1




2020     |     www.medigraphic.com